Neurotherapeutics

, Volume 6, Issue 3, pp 558–569

Oncolytic viral therapy of malignant glioma

Authors

  • Jacqueline Nuss Parker
    • Department of Pediatrics, Division of Infectious DiseasesUniversity of Alabama at Birmingham
  • David F. Bauer
    • Department of Surgery, Division of NeurosurgeryUniversity of Alabama at Birmingham
  • James J. Cody
    • Department of Pediatrics, Division of Infectious DiseasesUniversity of Alabama at Birmingham
    • Department of Surgery, Division of NeurosurgeryUniversity of Alabama at Birmingham
Review Article

DOI: 10.1016/j.nurt.2009.04.011

Cite this article as:
Parker, J.N., Bauer, D.F., Cody, J.J. et al. Neurotherapeutics (2009) 6: 558. doi:10.1016/j.nurt.2009.04.011

Summary

Novel approaches to treatment of malignant glioma, the most frequently occurring primary brain tumor, have included the use of a wide range of oncolytic viral vectors. These vectors, either naturally tumor-selective, or engineered as such, have shown promise in the handful of phase I and phase II clinical trials conducted in recent years. The strategies developed for each of the different viruses currently being studied and the history of their development are summarized here. In addition, the results of clinical trials in patients and their implication for future trials are also discussed.

Key Words

Oncolytic viral therapymalignant gliomaG207HSV 1716ONYX-015 adenovirusReolysinvacciniaNewcastle disease virusmeasles virus
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2009